Patents by Inventor Deborah A. Farson

Deborah A. Farson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8846385
    Abstract: Lentiviral vectors modified at the 5? LTR or both the 5? and 3? LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: September 30, 2014
    Assignee: GBP IP, LLC
    Inventors: Luigi Naldini, Thomas Dull, Deborah A. Farson, Rochelle Witt
  • Patent number: 8652837
    Abstract: Lentiviral vectors modified at the 5? LTR or both the 5? and 3? LTR are useful in the production of recombinant lentivirus vectors (See the Figure). Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production. The vectors can contain inducible or conditional promoters.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: February 18, 2014
    Assignee: GBP IP, LLC
    Inventors: Luigi Naldini, Thomas Dull, Anatoly Bukovsky, Deborah A. Farson, Rochelle Witt
  • Publication number: 20080286836
    Abstract: Lentiviral vectors modified at the 5? LTR or both the 5? and 3? LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.
    Type: Application
    Filed: July 26, 2006
    Publication date: November 20, 2008
    Applicant: Cell Genesys, Inc.
    Inventors: Luigi Naldini, Thomas Dull, Deborah A. Farson, Rochelle Witt
  • Patent number: 7252991
    Abstract: The invention provides a novel retroviral packaging system, in which retroviral packaging plasmids and packagable vector transcripts are produced from high expression plasmids after stable or transient transfection in mammalian cells. High titers of recombinant retrovirus are produced in these transfected mammalian cells and can then transduce a mammalian target cell by cocultivation or supernatant infection. The methods of the invention include the use of the novel retroviral packaging plasmids and vectors to transduce primary human cells, including T cells and human hematopoietic stem cells, with foreign genes by cocultivation or supernatant infection at high efficiencies. The invention is useful for the rapid production of high titer viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: August 7, 2007
    Assignee: Cell Genesys, Inc.
    Inventors: Mitchell H. Finer, Margo R. Roberts, Thomas J. Dull, Krisztina M. Zsebo, Lu Qin, Deborah A. Farson
  • Patent number: 7083981
    Abstract: Lentiviral vectors modified at the 5? LTR or both the 5? and 3? LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.
    Type: Grant
    Filed: July 21, 2005
    Date of Patent: August 1, 2006
    Assignee: Cell Genesys, Inc.
    Inventors: Luigi Naldini, Thomas Dull, Deborah A. Farson, Rochelle Witt
  • Patent number: 6924144
    Abstract: Lentiviral vectors modified at the 5? LTR or both the 5? and 3? LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: August 2, 2005
    Assignee: Cell Genesys, Inc.
    Inventors: Luigi Naldini, Thomas Dull, Deborah A. Farson, Rochelle Witt
  • Publication number: 20030199093
    Abstract: The invention provides a novel retroviral packaging system, in which retroviral packaging plasmids and packagable vector transcripts are produced from high expression plasmids after stable or transient transfection in mammalian cells. High titers of recombinant retrovirus are produced in these transfected mammalian cells and can then transduce a mammalian target cell by cocultivation or supernatant infection. The methods of the invention include the use of the novel retroviral packaging plasmids and vectors to transduce primary human cells, including T cells and human hematopoietic stem cells, with foreign genes by cocultivation or supernatant infection at high efficiencies. The invention is useful for the rapid production of high titer viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.
    Type: Application
    Filed: October 1, 2002
    Publication date: October 23, 2003
    Inventors: Mitchell H. Finer, Margo R. Roberts, Thomas J. Dull, Krisztina M. Zsebo, Lu Qin, Deborah A. Farson, Keegan Cooke
  • Patent number: 6506604
    Abstract: The invention provides a novel retroviral packaging system, in which retroviral packaging plasmids and packagable vector transcripts are produced from high expression plasmids after stable or transient transfection in mammalian cells. High titers of recombinant retrovirus are produced in these transfected mammalian cells and can then transduce a mammalian target cell by cocultivation or supernatant infection. The methods of the invention include the use of the novel retroviral packaging plasmids and vectors to transduce primary human cells, including T cells and, human hematopoietic stem cells, with foreign genes by cocultivation or supernatant infection at high efficiencies. The invention is is useful for the rapid production of high titer viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.
    Type: Grant
    Filed: September 4, 2001
    Date of Patent: January 14, 2003
    Assignee: Cell Genesys, Inc.
    Inventors: Mitchell H. Finer, Thomas J. Dull, Krisztina M. Zsebo, Keegan Cooke, Deborah A. Farson
  • Publication number: 20020173030
    Abstract: Lentiviral vectors modified at the 5′ LTR or both the 5′ and 3′ LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.
    Type: Application
    Filed: July 10, 2002
    Publication date: November 21, 2002
    Applicant: Cell Genesys, Inc.
    Inventors: Luigi Naldini, Thomas Dull, Deborah A. Farson, Rochelle Witt
  • Publication number: 20020106799
    Abstract: The invention provides a novel retroviral packaging system, in which retroviral packaging plasmids and packagable vector transcripts are produced from high expression plasmids after stable or transient transfection in mammalian cells. High titers of recombinant retrovirus are produced in these transfected mammalian cells and can then transduce a mammalian target cell by cocultivation or supernatant infection. The methods of the invention include the use of the novel retroviral packaging plasmids and vectors to transduce primary human cells, including T cells and human hematopoietic stem cells, with foreign genes by cocultivation or supernatant infection at high efficiencies. The invention is useful for the rapid production of high titer viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.
    Type: Application
    Filed: September 4, 2001
    Publication date: August 8, 2002
    Inventors: Mitchell H. Finer, Thomas J. Dull, Krisztina M. Zsebo, Keegan Cooke, Deborah A. Farson
  • Patent number: 6428953
    Abstract: Lentiviral vectors modified at the 5′ LTR or both the 5′ and 3′ LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: August 6, 2002
    Assignee: Cell Genesys, Inc.
    Inventors: Luigi Naldini, Thomas Dull, Deborah A. Farson, Rochelle Witt
  • Patent number: 6218187
    Abstract: The invention provides a novel retroviral packaging system, in which retroviral packaging plasmids and packagable vector transcripts are produced from high expression plasmids after stable or transient transfection in mammalian cells. High titers of recombinant retrovirus are produced in these transfected mammalian cells and can then transduce a mammalian target cell by cocultivation or supernatant infection. The methods of the invention include the use of the novel retroviral packaging plasmids and vectors to transduce primary human cells, including T cells and human hematopoietic stem cells, with foreign genes by cocultivation or supernatant infection at high efficiencies. The invention is useful for the rapid production of high titer viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.
    Type: Grant
    Filed: March 11, 1999
    Date of Patent: April 17, 2001
    Assignee: Cell Genesys, Inc.
    Inventors: Mitchell H. Finer, Thomas J. Dull, Krisztina M. Zsebo, Keegan Cooke, Deborah A. Farson
  • Patent number: 6165782
    Abstract: Lentiviral vectors modified at the 5' LTR or both the 5' and 3' LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.
    Type: Grant
    Filed: March 18, 1999
    Date of Patent: December 26, 2000
    Assignee: Cell Genesys, Inc.
    Inventors: Luigi Naldini, Thomas Dull, Deborah A. Farson, Rochelle Witt
  • Patent number: 6051427
    Abstract: The invention provides a novel retroviral packaging system, in which retroviral packaging plasmids and packagable vector transcripts are produced from high expression plasmids after stable or transient transfection in mammalian cells. High titers of recombinant retrovirus are produced in these transfected mammalian cells and can then transduce a mammalian target cell by cocultivation or supernatant infection. The methods of the invention include the use of the novel retroviral packaging plasmids and vectors to transduce primary human cells, including T cells and human hematopoietic stem cells, with foreign genes by cocultivation or supernatant infection at high efficiencies. The invention is useful for the rapid production of high titer viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.
    Type: Grant
    Filed: August 21, 1995
    Date of Patent: April 18, 2000
    Assignee: Cell Genesys, Inc.
    Inventors: Mitchell H. Finer, Margo R. Roberts, Thomas L. Dull, Krisztina M. Zsebo, Lu Qin, Deborah A. Farson
  • Patent number: 5994136
    Abstract: Lentiviral vectors modified at the 5' LTR or both the 5' and 3' LTR's are useful in the production of recombinant lentivirus vectors. Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: November 30, 1999
    Assignee: Cell Genesys, Inc.
    Inventors: Luigi Naldini, Thomas Dull, Deborah A. Farson, Rochelle Witt
  • Patent number: 5858740
    Abstract: The invention provides a novel retroviral packaging system, in which retroviral packaging constructs and packagable vector transcripts are produced from high expression plasmids by transfection in human cells. High titers of recombinant retrovirus are produced in infected cells. The methods of the invention include the use of the novel retroviral constructs to transduce primary human cells, including T cells and human hematopoietic stem cells, with foreign genes by cocultivation at high efficiencies. The invention is useful for the rapid production of high viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: January 12, 1999
    Assignee: Cell Genesys, Inc.
    Inventors: Mitchell H. Finer, Margo R. Roberts, Thomas J. Dull, Krisztina M. Zsebo, Lu Qin, Deborah A. Farson
  • Patent number: 5834256
    Abstract: The invention provides a novel retroviral packaging system, in which retroviral packaging constructs and packagable vector transcripts are produced from high expression plasmids by transfection in human cells. High titers of recombinant retrovirus are produced in infected cells. The methods of the invention include the use of the novel retroviral constructs to transduce primary human cells, including T cells and bone marrow stem cells, with foreign genes by cocultivation at high efficiencies. The invention is useful for the rapid production of high viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.
    Type: Grant
    Filed: June 11, 1993
    Date of Patent: November 10, 1998
    Assignee: Cell Genesys, Inc.
    Inventors: Mitchell H. Finer, Margo R. Roberts, Thomas J. Dull, Krisztina M. Zsebo, Lu Qin, Deborah A. Farson
  • Patent number: 5686279
    Abstract: The invention provides a novel retroviral packaging system, in which retroviral packaging constructs and packagable vector transcripts are produced from high expression plasmids by transfection in human cells. High titers of recombinant retrovirus are produced in infected cells. The methods of the invention include the use of the novel retroviral constructs to transduce primary human cells, including T cells and human hematopoietic stem cells, with foreign genes by cocultivation at high efficiencies. The invention is useful for the rapid production of high viral supernatants, and to transduce with high efficiency cells that are refractory to transduction by conventional means.
    Type: Grant
    Filed: June 10, 1994
    Date of Patent: November 11, 1997
    Assignee: Cell Genesys, Inc.
    Inventors: Mitchell H. Finer, Margo R. Roberts, Thomas J. Dull, Krisztina M. Zsebo, Lu Qin, Deborah A. Farson